Palmetto PeptidesPALMETTO PEPTIDES
Research Grade Quality★Fast USPS Priority Shipping★BPC-157 · TB-500 · Semaglutide · Tirzepatide★Premium Peptide Stacks★Third-Party Tested · COA Verified · Research Grade★Made in the USA★Research Grade Quality★Fast USPS Priority Shipping★BPC-157 · TB-500 · Semaglutide · Tirzepatide★Premium Peptide Stacks★Third-Party Tested · COA Verified · Research Grade★Made in the USA★

Palmetto Peptides Complete Guide to the Research Peptide GHK-Cu

Shopify API
March 31, 2026

Last Updated: March 26, 2026 Prepared by: Palmetto Peptides Research Team

IMPORTANT DISCLAIMERS: All information on this page is provided strictly for educational and scientific research purposes. GHK-Cu is a research compound sold exclusively for laboratory, in vitro, and preclinical research use. It is not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency for human consumption, human therapeutic use, veterinary use, or as a dietary supplement. Nothing on this page constitutes medical advice, clinical guidance, or encouragement to use this compound in any capacity outside of a properly controlled research setting. All referenced studies involve cell cultures and animal models unless explicitly stated otherwise. Consult peer-reviewed literature and appropriate regulatory guidance before initiating any research program involving this compound.

Palmetto Peptides Complete Guide to the Research Peptide GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is one of the most extensively studied research peptides in molecular biology, with over four decades of peer-reviewed literature examining its role in gene regulation, tissue remodeling signaling, antioxidant defense pathways, and extracellular matrix activity across multiple preclinical models. Naturally occurring in human plasma, its concentration declines measurably with age, making it a focal point for researchers in regenerative biology, geroscience, and cellular repair studies.

This guide compiles the current body of scientific literature on GHK-Cu, covering its molecular structure, mechanisms of action, relevant gene expression data, and the specific research areas where it has generated the most interest. All discussion is limited to findings from laboratory and animal model research. This compound is sold by Palmetto Peptides for research use only and carries no implied therapeutic application.

Table of Contents

  1. What Is GHK-Cu? Structure and Natural Origin
  2. How GHK-Cu Works: Mechanisms of Action in Research Models
  3. GHK-Cu and Gene Expression: The Broad Institute Data
  4. Research Areas: What the Science Has Examined
  5. Skin and Extracellular Matrix Research
  6. Wound Healing Signaling
  7. Lung and Pulmonary Research
  8. Antioxidant and Anti-Inflammatory Pathways
  9. Neurological and Cognitive Research Models
  10. Inflammatory Bowel Research
  11. GHK-Cu and the Aging Genome: A Research Summary
  12. Research Data at a Glance: Key Figures and Findings
  13. GHK-Cu vs. Related Research Peptides
  14. Sourcing GHK-Cu for Research: What to Look For
  15. Frequently Asked Questions
  16. Peer-Reviewed Citations

What Is GHK-Cu? Structure and Natural Origin

GHK-Cu is the copper-bound complex of the tripeptide glycyl-L-histidyl-L-lysine, a short three-amino-acid chain that occurs naturally in human plasma, saliva, and urine. The peptide was first isolated in 1973 by Loren Pickart, who discovered it while studying a fraction of human plasma albumin that caused older liver tissue to synthesize proteins more characteristic of younger tissue. That early observation launched decades of research into what GHK-Cu does at the molecular level.

The tripeptide's name reflects its amino acid sequence: glycine, histidine, and lysine. On its own, GHK already demonstrates biological signaling activity in laboratory settings. When bound to a copper(II) ion (Cu2+), which it does with an affinity comparable to albumin's copper transport sites, it forms the GHK-Cu complex that is the primary subject of most published research. The copper binding is not incidental. Copper is an essential cofactor for more than a dozen enzymes involved in connective tissue synthesis, antioxidant defense, and cellular respiration, and GHK appears to facilitate copper uptake and bioavailability in cellular environments.

Why Plasma Levels Matter to Researchers

One of the more compelling observations driving GHK-Cu research is what happens to its plasma concentration as an organism ages. At age 20, plasma GHK levels sit at roughly 200 ng/mL. By age 60, that figure has dropped to approximately 80 ng/mL. This decline runs roughly parallel to well-documented decreases in regenerative capacity, wound healing speed, and tissue repair efficiency that occur with aging. Researchers in geroscience and longevity biology have paid particular attention to this correlation, though causality between GHK-Cu levels and aging-related tissue changes has not been established in humans.

Related Product: GHK-Cu Research Peptide (Palmetto Peptides) | For Research Use Only

How GHK-Cu Works: Mechanisms of Action in Research Models

The reason GHK-Cu appears in so many different areas of preclinical research comes down to its unusually broad range of molecular interactions. Rather than targeting a single receptor or pathway, it appears to function more like a signaling modulator, influencing activity across multiple interconnected biological systems simultaneously.

Copper Transport and Enzymatic Cofactor Activity

At the most fundamental level, GHK-Cu's binding of copper ions gives it immediate relevance to any cellular pathway that depends on copper as a cofactor. This includes lysyl oxidase (critical for collagen and elastin cross-linking), superoxide dismutase (a key antioxidant enzyme), and cytochrome c oxidase (central to cellular energy production). By facilitating copper transport and reducing the pool of free ionic copper available to catalyze harmful oxidative reactions, GHK-Cu simultaneously supports enzymatic function and reduces oxidative stress in model systems.

Activation of TGF-Beta and Integrin Pathways

Research in lung fibroblasts has demonstrated that GHK-Cu can restore activity of the TGF-beta (transforming growth factor-beta) pathway, which governs a wide range of tissue repair and remodeling processes. In the landmark COPD fibroblast studies discussed in more detail below, GHK-Cu treatment restored impaired collagen contraction and remodeling capacity, and elevated integrin beta-1 expression. The TGF-beta and integrin pathways are known to interact, and GHK-Cu's ability to influence both simultaneously has made it a useful tool for researchers studying tissue regeneration signaling.

NFkB Suppression and Inflammatory Signaling

Multiple laboratory studies have examined GHK-Cu's effects on the nuclear factor kappa-B (NF-kB) pathway, a central regulator of inflammatory gene expression. In animal models of acute lung injury and emphysema, GHK-Cu treatment was associated with suppression of NF-kB p65 phosphorylation, along with reductions in pro-inflammatory cytokines including TNF-alpha and IL-6. These findings position GHK-Cu as a useful research tool for studying the intersection of oxidative stress and inflammatory signaling.

Nrf2 Pathway Upregulation

Research in cigarette smoke-induced emphysema models showed that GHK-Cu upregulated the Nrf2/Keap1 antioxidant pathway, which governs the expression of numerous genes involved in redox balance. This included effects on glutathione synthesis, a critical cellular antioxidant. The Nrf2 pathway has attracted substantial research attention in the context of aging and chronic inflammatory conditions, and GHK-Cu represents one of the more well-characterized naturally derived peptides that appear to engage it.

SIRT1 and STAT3 Interaction

More recent molecular docking analysis published in 2025 identified SIRT1 (NAD-dependent deacetylase sirtuin-1) as a direct binding target for GHK-Cu, with a binding energy of -8.75 kcal/mol. SIRT1 is one of the sirtuins most closely associated with cellular metabolism, stress response, and longevity-related research. The same research demonstrated that GHK-Cu modulated the SIRT1-STAT3 axis, a pathway involved in inflammatory regulation, in an experimental colitis model. This newly characterized mechanism connects GHK-Cu research to some of the most active areas in aging biology.

Proteasome System Activation

Gene expression data suggests GHK-Cu strongly upregulates the ubiquitin-proteasome system (UPS), with research identifying increased expression of 41 UPS-related genes and suppression of just 1. The proteasome is the cell's primary system for clearing misfolded and damaged proteins, and its declining activity with age has been linked to the accumulation of toxic protein aggregates in neurodegenerative research contexts.

GHK-Cu and Gene Expression: The Broad Institute Data

One of the most frequently cited bodies of data on GHK-Cu comes from genomic profiling work using the Broad Institute's Connectivity Map (cMap), a software tool that matches gene expression signatures with known bioactive compounds. This approach has been used to analyze GHK's effects on gene activity across thousands of genes simultaneously.

The numbers that emerge from this work are striking. Research has identified that GHK-Cu can influence the expression of more than 4,000 human genes, with some analyses estimating that it affects approximately 31.2% of the human genome by the criterion of producing greater than 50% change in gene activity in either direction. The general pattern observed is one that researchers describe as a "resetting" of gene expression toward patterns more characteristic of younger or healthier tissue states.

Key Gene Categories Affected

The breadth of GHK-Cu's genomic influence spans several functional categories:

Antioxidant Genes: Research documents increased expression of 14 antioxidant genes alongside suppression of 2 pro-oxidant genes. The anti-inflammatory inhibitor IL18BP showed a 295% increase in expression, and TLE1 (an inflammatory suppressor) showed a 762% increase, both suggesting a coordinated shift toward lower inflammatory tone.

DNA Repair Genes: GHK-Cu has been primarily stimulatory for DNA repair gene expression, with 47 upregulated and only 5 downregulated in published analyses. This pattern has attracted attention from researchers studying radiation damage and genomic instability.

Tissue Remodeling Genes: Modulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) has been documented, with the net effect pointing toward organized matrix remodeling rather than disorganized degradation.

Cancer-Related Gene Suppression: In an analysis published using colorectal cancer gene expression data, GHK at 1 micromolar suppressed RNA production in 70% of 54 genes overexpressed in metastatic cancer patients, including node molecules like YWHAB, MAP3K5, and NFATC2. This occurred at a concentration described as low and non-toxic in the research context.

Nervous System Genes: Research on nervous system-relevant gene expression identified GHK-Cu's influence on pathways related to neuronal survival, axonal growth, and the ubiquitin-proteasome system, which has implications for neurodegeneration research.

Related Products: Explore Palmetto Peptides' Full Research Peptide Catalog | For Research Use Only

Research Areas: What the Science Has Examined

Skin and Extracellular Matrix Research

The largest body of published GHK-Cu research exists in the context of skin biology and extracellular matrix (ECM) remodeling. The compound's known ability to stimulate collagen and elastin synthesis, support fibroblast function, and modulate glycosaminoglycan production has made it a cornerstone of skin aging research at the cellular level.

Fibroblasts are the primary cell type responsible for synthesizing the structural proteins that give skin its mechanical integrity. Research has consistently demonstrated that GHK-Cu supports fibroblast activity, promotes the organized deposition of collagen, and helps regulate the balance between matrix synthesis and degradation. Importantly, this modulation appears to favor organized structural repair rather than fibrotic scarring patterns.

A 2023 investigator-initiated clinical study examining a topical GHK-Cu gel formulation in 21 female volunteers reported an average increase in skin collagen density of 28% after three months of daily application, with the top quartile of subjects showing a 51% increase as measured by high-resolution dermal ultrasound. While this represents early-stage clinical observation in a small cohort, it represents one of the few instances where GHK-Cu's preclinical ECM signaling data has been examined in a controlled topical formulation context.

The peptide also influences matrix metalloproteinase regulation in ways that researchers describe as "remodeling-favorable," reducing the kind of disorganized matrix breakdown associated with photoaging and inflammatory skin damage while supporting organized structural turnover.

Related Supporting Article: How Collagen Synthesis Research Peptides Work | For Educational Purposes Only

Related Product: GHK-Cu Powder (Palmetto Peptides) | For Research Use Only

Wound Healing Signaling

Wound healing research has been another major area of GHK-Cu investigation in preclinical models. The compound's influence on multiple overlapping processes relevant to repair including angiogenesis, fibroblast migration, collagen deposition, and inflammatory regulation has made it a useful research tool in this context.

Animal model studies have examined GHK-Cu's effects on wound contraction, granulation tissue formation, antioxidant enzyme activity, and blood vessel growth in experimental wound models. In studies involving collagen dressings incorporating GHK, treated groups demonstrated elevated glutathione and ascorbic acid levels, improved epithelialization, and increased collagen synthesis compared to controls. In healthy rat models, GHK-incorporated collagen dressings produced approximately a nine-fold increase in collagen synthesis compared to untreated wounds.

Research has also examined GHK-Cu in ischemic wound models, where impaired vascularization complicates repair signaling. The peptide's known effects on vascular endothelial growth factor (VEGF) expression and angiogenic signaling make it particularly relevant to these models.

More recent work has explored novel delivery systems, including GHK-Cu-silver nanoparticle conjugates (GHK-Cu-AgNPs), which have been studied in both in vitro fibroblast models and in vivo wound models for their combined antimicrobial and pro-regenerative signaling properties.

Lung and Pulmonary Research

Among the most scientifically significant GHK-Cu research findings is a landmark collaborative study conducted by scientists from Boston University, the University of Groningen, the University of British Columbia, and the University of Pennsylvania, examining the peptide's relationship to gene expression patterns in chronic obstructive pulmonary disease (COPD).

Using the Broad Institute's Connectivity Map, researchers identified 127 genes whose expression was significantly associated with emphysema severity. In COPD-affected tissue, inflammation-related genes were upregulated while tissue remodeling and repair genes, particularly those in the TGF-beta pathway, were downregulated. When GHK was identified as a compound whose gene signature was the opposite of the COPD pattern, researchers tested it directly in vitro.

The results were notable: GHK at 10 nM, added to cultured lung fibroblasts from emphysematous tissue, reversed the gene expression pattern from tissue destruction to tissue repair. Treated fibroblasts regained the ability to contract and remodel collagen gel, displayed organized actin cytoskeletal structure, and showed elevated integrin beta-1 expression. These are among the most mechanistically compelling findings in the GHK-Cu literature because the in vitro results confirmed what the computational gene signature predicted.

Subsequent animal research in cigarette smoke-induced emphysema models demonstrated that GHK-Cu treatment attenuated emphysematous tissue changes, partially corrected imbalances in the MMP-9/TIMP-1 ratio, suppressed NF-kB inflammatory signaling, and activated the Nrf2/Keap1 antioxidant pathway in lung tissue.

Related Supporting Article: Peptide Research and Pulmonary Tissue Models | For Educational Purposes Only

Antioxidant and Anti-Inflammatory Pathways

GHK-Cu's antioxidant activity in research models operates through several complementary mechanisms. As a copper chelator, it reduces the pool of free ionic copper available to catalyze harmful Fenton-type reactions that generate hydroxyl radicals. It upregulates superoxide dismutase (SOD), a front-line antioxidant enzyme. It quenches certain lipid peroxidation byproducts. And through its influence on Nrf2, it promotes broader antioxidant gene expression.

In acute lung injury animal models, GHK-Cu treatment increased SOD activity while decreasing TNF-alpha and IL-6 levels, two of the most prominent markers of acute inflammatory signaling. The mechanism involved suppression of NF-kB p65 and p38 MAPK phosphorylation in lung cells.

Its anti-inflammatory activity extends to the suppression of fibrinogen, a protein associated with both clotting and chronic inflammatory states. Research has documented GHK-Cu's ability to modulate the expression of fibrinogen-related genes, which has attracted attention from researchers studying cardiovascular risk markers.

The coordination of antioxidant and anti-inflammatory signaling in GHK-Cu research models is particularly compelling because the two pathways are closely interrelated. Oxidative stress drives inflammatory gene expression through NF-kB activation, while inflammatory signaling generates additional reactive oxygen species. GHK-Cu's simultaneous engagement of both pathways suggests it may be a useful tool for studying how these systems interact.

Neurological and Cognitive Research Models

Research into GHK-Cu's neurological relevance is earlier stage than its skin or pulmonary research base, but the preliminary data has attracted meaningful scientific attention. The compound's known effects on the ubiquitin-proteasome system, nerve growth signaling, and antioxidant defense make it biologically relevant to neurodegeneration research contexts.

In vitro studies have examined GHK-Cu's effects on neuronal cell models, including its influence on axonal growth, differentiation markers, and oxidative stress resistance. Importantly, gene expression data suggests GHK strongly stimulates UPS gene expression, with 41 relevant genes upregulated. The UPS is the cell's primary mechanism for clearing misfolded proteins, including those implicated in neurodegenerative conditions, and its activity declines with age.

A 2023 preprint study using a 5xFAD mouse model of Alzheimer's disease examined intranasal delivery of GHK-Cu over a 12-week period. Results included improved cognitive performance on behavioral tests, reduced amyloid plaque deposition, and decreased MCP-1-mediated neuroinflammation in the frontal cortex and hippocampus. Researchers noted that intranasal delivery allowed access to the brain through the olfactory and trigeminal pathways, bypassing the blood-brain barrier while maintaining low systemic copper levels. The study characterized this as early-stage preclinical research requiring replication in additional model systems.

GHK-Cu has also been noted in the context of anti-anxiety and anti-aggression research in animal models, observations that emerged from gene expression analyses showing effects on nervous system-relevant pathways.

Inflammatory Bowel Research

A 2025 study published in Frontiers in Pharmacology examined GHK-Cu's effects in a dextran sulfate sodium (DSS)-induced colitis mouse model, one of the most commonly used preclinical models for ulcerative colitis research. The study identified SIRT1 as a novel direct binding target for GHK-Cu through molecular docking analysis, with the binding energy of -8.75 kcal/mol indicating meaningful molecular interaction.

In DSS-induced mice, GHK-Cu significantly upregulated SIRT1 expression in colon tissue and modulated the SIRT1-STAT3 signaling axis, which is involved in intestinal barrier function and inflammatory regulation. Treated animals showed improved markers of intestinal barrier integrity, including changes in tight junction proteins ZO-1 and Occludin, alongside reductions in pro-inflammatory cytokines IL-6, IL-1beta, and TNF-alpha.

This research is notable for expanding the understanding of GHK-Cu's mechanisms beyond the TGF-beta and NF-kB pathways that have historically dominated the literature, connecting it to the sirtuin biology that has become central to aging and metabolic research.

GHK-Cu and the Aging Genome: A Research Summary

The thread that runs through nearly all GHK-Cu research is its relationship to aging processes at the molecular level. The data points, when assembled, tell a consistent story worth summarizing clearly.

Natural GHK levels are highest in young, healthy individuals. Plasma concentration drops by roughly 60% between age 20 and age 60. Coinciding with this decline are measurable reductions in tissue repair speed, collagen density, immune regulation efficiency, and resistance to oxidative damage. Whether GHK-Cu decline is causative of these changes, correlative, or simply part of a larger pattern of biological aging remains an open research question.

What is better established, in preclinical models, is that supplementing cellular environments with GHK-Cu tends to shift gene expression patterns toward those characteristic of younger or less damaged tissue states. The genomic data from Connectivity Map analyses, the fibroblast studies in COPD tissue, the wound healing data in diabetic models, and the SIRT1 activation findings all point in a similar direction: GHK-Cu engages multiple systems that decline with age and appears to counteract some aspects of that decline at the molecular level in controlled research settings.

This is why GHK-Cu occupies an unusual position in peptide research. It is not a novel synthetic compound targeting a single engineered receptor. It is a naturally occurring tripeptide with a half-century of published research, a well-characterized endogenous decline pattern, and a mechanistic footprint that spans antioxidant defense, inflammatory regulation, tissue repair signaling, proteasome activation, and genome-wide gene expression modulation.

Research Data at a Glance: Key Figures and Findings

The table below summarizes key quantitative findings from published GHK-Cu preclinical research. All figures are from cell culture or animal model studies unless noted.

Research Area Key Finding Study Context
Gene influence Modulates expression of 4,000+ human genes Broad Institute Connectivity Map analysis
Genome coverage Affects approx. 31.2% of human genome Based on greater than 50% expression change criterion
DNA repair genes 47 upregulated, 5 downregulated Gene expression profiling
Antioxidant genes 14 upregulated, 2 prooxidant genes suppressed Gene expression profiling
TLE1 (anti-inflammatory) 762% increase in expression Gene expression data
IL18BP (anti-inflammatory) 295% increase in expression Gene expression data
UPS genes 41 upregulated, 1 downregulated Nervous system gene expression research
Collagen synthesis (rat wound model) Approximately 9-fold increase PIC-GHK collagen dressing study
Plasma GHK at age 20 ~200 ng/mL Human plasma concentration data
Plasma GHK at age 60 ~80 ng/mL Human plasma concentration data
COPD-associated genes identified 127 genes correlated with emphysema severity Campbell et al. multi-institution study
Cancer gene suppression 70% of 54 metastatic genes suppressed Colorectal cancer gene expression analysis
SIRT1 binding energy -8.75 kcal/mol Molecular docking analysis, 2025
Skin collagen density (clinical observation) Average 28% increase over 3 months Small-cohort topical formulation study, n=21

Note: All values represent findings from in vitro and animal model studies, or small-scale observational research, unless explicitly noted. These figures are not evidence of efficacy in humans for any therapeutic purpose.

Researchers studying tissue repair, anti-aging biology, or extracellular matrix modulation often evaluate GHK-Cu alongside other research peptides. Understanding where it sits relative to related compounds is useful for research design.

GHK-Cu vs. BPC-157: BPC-157 (body protective compound-157) is a 15-amino-acid synthetic peptide derived from a sequence in gastric protein. Both peptides have been studied in wound healing and tissue repair models, but their mechanisms differ substantially. BPC-157 research has focused heavily on tendon, muscle, and gastrointestinal tissue models, while GHK-Cu's most distinctive feature is its documented genomic footprint across thousands of genes. GHK-Cu's copper-binding mechanism is also unique to its biology.

GHK-Cu vs. Matrixyl (Palmitoyl Tripeptide-1): Palmitoyl tripeptide-1, also known commercially as Matrixyl, is a palmitoylated derivative of GHK itself. The palmitoyl modification enhances lipid solubility for topical delivery applications and has been studied in cosmetic research contexts. Matrixyl and GHK-Cu share a common tripeptide backbone but differ in their delivery characteristics, stability profiles, and intended applications.

GHK-Cu vs. TB-500 (Thymosin Beta-4): TB-500 is a synthetic version of a peptide fragment derived from thymosin beta-4, studied primarily for its effects on actin regulation, angiogenesis, and wound healing. Both peptides have been examined in wound and tissue repair models, but their mechanisms are distinct. GHK-Cu's gene regulation activity is considerably more extensively characterized in the published literature.

Related Products: - BPC-157 Research Peptide (Palmetto Peptides) | For Research Use Only - TB-500 Research Peptide (Palmetto Peptides) | For Research Use Only - Explore All Tissue Repair Research Peptides | For Research Use Only

Sourcing GHK-Cu for Research: What to Look For

Research integrity depends on compound quality. For any research peptide, purity verification through independent third-party testing is a non-negotiable baseline. When evaluating a GHK-Cu source for research use, consider the following:

Purity Verification: Look for suppliers who provide current third-party certificates of analysis (CoA) showing purity levels (typically greater than 98% for research-grade material) via HPLC or mass spectrometry. CoA documents should be specific to the lot you are purchasing, not generic.

Identity Confirmation: Mass spectrometry confirmation of molecular weight is the gold standard for peptide identity verification. The molecular formula for GHK-Cu is C14H22CuN6O4, with a molecular weight of approximately 397.87 g/mol for the copper-bound complex.

Storage Recommendations: GHK-Cu in lyophilized powder form should be stored at -20 degrees Celsius, protected from light and moisture. Once reconstituted, solutions should be aliquoted to avoid repeated freeze-thaw cycles and used promptly.

Regulatory Compliance: All purchases should be made from suppliers who clearly communicate that products are for research use only, who do not make health claims, and who maintain documentation supporting regulatory compliance for research reagent distribution.

Palmetto Peptides GHK-Cu: View Product Page | Third-party tested, research use only, lot-specific CoA available.

Frequently Asked Questions

What is GHK-Cu?

GHK-Cu is the copper-bound form of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (GHK). It was first isolated from human plasma in 1973 and has since become one of the most studied research peptides in molecular biology, with applications across gene regulation research, tissue repair modeling, antioxidant pathway studies, and more. It is available from Palmetto Peptides exclusively for laboratory research purposes.

How does GHK-Cu differ from GHK alone?

GHK on its own is a tripeptide, while GHK-Cu refers to the complex formed when GHK binds to a copper(II) ion. The copper-bound form demonstrates an affinity for Cu2+ comparable to albumin's copper transport sites, which research suggests enhances its bioavailability and biological activity in preclinical models compared to the unbound peptide.

How many genes does GHK-Cu influence in research models?

Research using the Broad Institute's Connectivity Map and genome-wide profiling has identified that GHK-Cu can influence the expression of more than 4,000 human genes. Some analyses estimate it affects approximately 31.2% of the human genome based on a criterion of greater than 50% change in expression level, affecting genes involved in antioxidant defense, DNA repair, tissue remodeling, inflammatory regulation, and nervous system function.

What tissue types have been studied in connection with GHK-Cu research?

Preclinical research has examined GHK-Cu's signaling activity across a range of tissue types including skin, lung connective tissue, bone, liver, gastric lining, skeletal muscle, colon, and neuronal cell models. All studies referenced in this guide involve in vitro cell culture or in vivo animal models.

Is GHK-Cu approved by the FDA for any use?

No. GHK-Cu is not approved by the U.S. Food and Drug Administration as a drug, therapeutic agent, dietary supplement, or for any medical application. It is available as a research compound for laboratory use only, and is not approved for human or animal consumption or medical application. Palmetto Peptides sells GHK-Cu strictly for research purposes.

What is GHK-Cu's relationship to aging at the molecular level?

Research has documented that plasma GHK levels decline with age, from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60. This decline parallels measurable reductions in tissue regenerative capacity. Whether this relationship is causal has not been established in humans. GHK-Cu is studied in preclinical models as a tool for examining aging-related changes in gene expression and tissue repair signaling.

Where can I purchase GHK-Cu for research purposes?

Palmetto Peptides offers research-grade GHK-Cu for qualified laboratory use. All products are verified through third-party testing, supplied with lot-specific certificates of analysis, and are intended strictly for in vitro and preclinical research use. View the GHK-Cu product page here.

Peer-Reviewed Citations

The following peer-reviewed and scientific publications are referenced throughout this guide. All citations are provided for informational purposes to support researchers in locating primary sources.

  1. Pickart L, Thaler MM. "Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver." Nature New Biology. 1973;243(124):85-87.

  2. Pickart L, Freedman JH, Loker WJ, et al. "Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells." Nature. 1980;288(5791):715-717. doi:10.1038/288715a0

  3. Pickart L, Vasquez-Soltero JM, Margolina A. "GHK and DNA: Resetting the Human Genome to Health." BioMed Research International. 2014;2014:151479. doi:10.1155/2014/151479

  4. Pickart L, Vasquez-Soltero JM, Margolina A. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108

  5. Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987 (PMC6073405)

  6. Pickart L, Vasquez-Soltero JM, Margolina A. "The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline." Brain Sciences. 2017;7(2):20. doi:10.3390/brainsci7020020 (PMC5332963)

  7. Campbell JD, McDonough JE, Zeskind JE, et al. "A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK." Genome Medicine. 2012;4(8):67. doi:10.1186/gm367

  8. Zhang Y, et al. "Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway." Frontiers in Molecular Biosciences. 2022;9:925700. doi:10.3389/fmolb.2022.925700

  9. Mao X, Huang Y, Li B, et al. "Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms." Frontiers in Pharmacology. 2025;16:1551843. doi:10.3389/fphar.2025.1551843 (PMC12263609)

  10. Tucker M, Liao GY, Park JY, et al. "Behavioral and neuropathological features of Alzheimer's disease are attenuated in 5xFAD mice treated with intranasal GHK peptide." bioRxiv. 2023. doi:10.1101/2023.11.20.567908

  11. Li X, et al. "Thermodynamically stable ionic liquid microemulsions pioneer pathways for topical delivery and peptide application." Journal of Controlled Release. 2024. (PMC10643103)

  12. Gorouhi F, Maibach HI. "Role of topical peptides in preventing or treating aged skin." Skin Pharmacology and Physiology. 2009;22(5):228-247. doi:10.1159/000228335

  13. Deng R, et al. "GHK-Cu promotes skeletal muscle healing." Published 2023. (Referenced in: Mao et al., 2025)

  14. Klontzas ME, et al. "Bone-related effects of GHK-Cu." Published 2019. (Referenced in: Mao et al., 2025)

  15. Lamb J. "The Connectivity Map: A new tool for biomedical research." Nature Reviews Cancer. 2007;7(1):54-60. doi:10.1038/nrc2044

Legal Notice: GHK-Cu is sold by Palmetto Peptides strictly as a research compound for in vitro and preclinical laboratory use only. It is not a drug, supplement, or therapeutic agent, and it has not been evaluated or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body for any medical application. It is not intended for human consumption, human therapeutic use, or veterinary use of any kind. Research findings described herein are from published cell culture and animal model studies and do not constitute evidence of efficacy or safety in humans. Nothing on this page should be interpreted as medical advice or as a recommendation to use this compound for any purpose outside of a properly controlled, legally sanctioned research setting. Researchers are responsible for ensuring all use of this compound complies with applicable local, state, and federal regulations.

Palmetto Peptides Research Team Last Updated: March 26, 2026

Related Research in This GHK-Cu Series

More Research Articles

Peptide Reconstitution Calculator: The Complete Guide to Dosing Math for Research Labs

Apr 9, 2026

Bacteriostatic Water for Peptide Research: What It Is, Why It Matters, and How to Use It

Apr 9, 2026

Analytical Testing Methods for High-Purity Tesamorelin in Scientific Research Settings

Apr 6, 2026